Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: HEPAMUT - Mutated Neoantigens in Hepatocellular Carcinoma

PROVIDER: PRJNA801457 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25434473_1.fastq.gz	Fastqsanger.gz
	SRR25434473_2.fastq.gz	Fastqsanger.gz
	SRR25434474_1.fastq.gz	Fastqsanger.gz
	SRR25434474_2.fastq.gz	Fastqsanger.gz
	SRR25434475_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 40

Similar Datasets

Expression of mutated genes in tumor samples in patients with hepatocellular carcinoma

Project description:Expression of mutated genes (mRNA) in tumor cells may originate new protein sequences potentially recognized by lymphocytes, denominated neoantigens. The purpose of this study is the chracterization of the expression of mutated genes in tumor samples in patients with hepatocellular carcinoma. Expression of the mutated genes are compared with that of the wild-type (WT) version in the tumor cells, Moreover, expression of these mutated and WT genes is also analyzed in non-tumoral lver tissue. Thse comparative experiments have allowed to demostrated specific expression of mutated genes in tumor cells obtained from patients.

2022-01-18 | GSE193567 | GEO

Ultra-deep sequencing of plasma DNA identifies druggable mutations in hepatocellular carcinoma

Project description:The purpose of the study is to detect somatic mutations in hepatocellular carcinoma using circulating free-DNA. We used deep-sequencing data of a panel of 60 commonly mutated genes in hepatocellular carcinoma.

2018-04-29 | E-MTAB-5123 | biostudies-arrayexpress

Deep targeted sequencing of multiregional sampling in hepatocellular carcinoma

Project description:The purpose of this experiment of high-coverage DNA sequencing of 58 frequently mutated genes in hepatocellular carcinoma (HCC) is to confirm clonal distribution of the known HCC drivers in samples corresponding to multiple regions of a tumor.

2020-01-16 | E-MTAB-5899 | biostudies-arrayexpress

Gene expression profile of TARDBP in hepatocellular carcinoma cell line (SK-Hep1)

Project description:TARDBP is TARDBP (TDP-43) is a DNA/RNA binding protein and was mutated in human amyotrophic lateral sclerosis (ALS). However, its function in human cancer has not been fully identified, yet.Thus, We carried out microarray to investigate the down-stream target genes of TARDBP after silencing TARDBP in liver cancer cell SK-Hep1. To identify the role of TARDBP in hepatocellular carcinoma cell line, we performed microarray after knocking down TARDBP in hepatocellular carcinoma cell line (3 siLuc, 3 siTARDBP)

2013-04-22 | E-GEOD-37640 | biostudies-arrayexpress

UNC Hepatocellular Carcinoma Study by Exome Sequencing (HCCSES)

Project description:<p>Genetic alterations in specific driver genes lead to disruption of cellular pathways and are critical events in the instigation and progression of hepatocellular carcinoma. As a prerequisite for individualized cancer treatment, we sought to characterize the landscape of recurrent somatic mutations in hepatocellular carcinoma. We performed whole exome sequencing on 87 hepatocellular carcinomas and matched normal adjacent tissues to an average coverage of 59x. The overall mutation rate was roughly 2 mutations per Mb, with a median of 45 non-synonymous mutations that altered the amino acid sequence (range 2 to 381). We found recurrent mutations in several genes with high transcript levels: TP53 (18%), CTNNB1 (10%), KEAP1 (8%), C16orf62 (8%), MLL4 (7%) and RAC2 (5%). Significantly affected gene families include the nucleotide-binding domain and leucine rich repeat containing family, calcium channel subunits, and histone methyltransferases. In particular, the MLL family methyltransferases for histone H3 lysine 4 were mutated in 20% of tumors. Conclusion: The NFE2L2-KEAP1 and MLL pathways are recurrently mutated in multiple cohorts of hepatocellular carcinoma.</p>

| phs000627 | dbGaP

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

Project description:The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma, a lethal disease lacking specific therapies. This study reports on the identification, characterization, and immunotherapeutic application of HLA-presented neoantigens specific for the DNAJB1-PRKACA fusion transcript in fibrolamellar hepatocellular carcinoma. DNAJB1-PRKACA-derived HLA class I and HLA class II ligands induce multifunctional cytotoxic CD8+ and T-helper 1 CD4+ T cells, and their cellular processing and presentation in DNAJB1-PRKACA expressing tumor cells is demonstrated by mass spectrometry-based immunopeptidome analysis. Single-cell RNA sequencing further identifies multiple T cell receptors from DNAJB1-PRKACA-specific T cells. Vaccination of a fibrolamellar hepatocellular carcinoma patient, suffering from recurrent short interval disease relapses, with DNAJB1-PRKACA-derived peptides under continued Poly (ADP-ribose) polymerase inhibitor therapy induces multifunctional CD4+ T cells, with an activated T-helper 1 phenotype and high T cell receptor clonality. Vaccine-induced DNAJB1-PRKACA-specific T cell responses persist over time and, in contrast to various previous treatments, are accompanied by durable relapse free survival of the patient for more than 21 months post vaccination. Our preclinical and clinical findings identify the DNAJB1-PRKACA protein as source for immunogenic neoepitopes and corresponding T cell receptors and provide efficacy in a single-patient study of T cell-based immunotherapy specifically targeting this oncogenic fusion.

2022-10-13 | PXD029882 | Pride

Comprehensive analysis of the miRNA profile between HBV-related Hepatocellular carcinoma (HBCC) and no HBV-related Hepatocellular carcinoma (HNCC)

Project description:To explore the miRNA expression profiles between HBV-related Hepatocellular carcinoma and no HBV-related Hepatocellular carcinoma To performe microarray analysis to detect the miRNA expression profiles between HBV-related Hepatocellular carcinoma and no HBV-related Hepatocellular carcinoma

2021-05-29 | GSE151441 | GEO

Activation of beta-catenin in hepatocellular carcinoma (mouse Ctnnb1 knockout)

Project description:CTNNB1 is the most frequently mutated gene in hepatocellular carcinoma (HCC). However, its clinical relevance remains controversial. We determined an evolutionarily conserved β-catenin signature by comparative analysis of gene expression data from human HCC (GSE43619) and a mouse model.

2014-12-31 | GSE43628 | GEO

Single cell RNA-seq and TCR-seq of T cell responses against DNAJB1-PRKACA

Project description:The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma (FL-HCC), a lethal disease lacking specific therapies. Here, we report on the identification, characterization and first immunotherapeutic application of HLA-presented neoantigens specific for the DNAJB1-PRKACA fusion transcript in FL-HCC. To characterize the T cell response against DNAJB1-PRKACA-derived HLA class I and HLA class II ligands, single cell RNA sequencing (scRNA-seq) and single cell TCR profiling from CD4+ and CD8+ T cells were performed using 10x Genomics single cell immune profiling.

2022-09-12 | GSE210337 | GEO

Expression of mutated genes in tumor samples in patients with hepatocellular carcinoma

Project description:Expression of mutated genes in tumor samples in patients with hepatocellular carcinoma

| PRJNA796607 | ENA